Importance Prostate cancer is the most common cancer diagnosis made in men with more
than 160 000 new cases each year in the United States. Although it often has an indolent …

Importance Prostate cancer is the second leading cause of cancer death among US men.
Objective To systematically review evidence on prostate-specific antigen (PSA)–based …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Importance Understanding adverse effects of contemporary treatment approaches for men
with favorable-risk and unfavorable-risk localized prostate cancer could inform treatment …

Importance The optimal treatment for Gleason score 9-10 prostate cancer is unknown.
Objective To compare clinical outcomes of patients with Gleason score 9-10 prostate cancer …

Background Long-term patient-reported outcomes are needed to inform treatment decisions
for localized prostate cancer. Methods Patient-reported outcomes of 1643 randomly …

Context Current evidence-based management for clinically localised prostate cancer
includes active surveillance, surgery, external beam radiotherapy (EBRT) and …

Importance Treatment-related regret is an integrative, patient-centered measure that
accounts for morbidity, oncologic outcomes, and anxiety associated with prostate cancer …

Purpose In April 2017, the American Urological Association, American Society for Radiation
Oncology, and Society of Urologic Oncology released a joint evidence-based practice …

Background Little is known about the health-related quality of life (HRQOL) of men living
with advanced prostate cancer. We report population-wide functional outcomes and HRQOL …